Experimental blood cancer drug trial halted early – what happened?
NCT ID NCT04240704
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 32 times
Summary
This early-stage study tested a new drug called JBH492 in 25 people with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL) whose cancer had returned or stopped responding to prior treatments. The main goal was to check the drug's safety and find the right dose. The trial was terminated early, meaning it stopped before completion, so no final conclusions about effectiveness could be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Helsinki, FIN-00029, Finland
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 0045, Japan
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
Conditions
Explore the condition pages connected to this study.